Showing 5531-5540 of 5771 results for "".
- MPOD Measurement Earns American Medical Association CPT III Codehttps://modernod.com/news/mpod-measurement-earns-american-medical-association-cpt-iii-code/2480039/EyePromise announced that on July 1, 2018, macular pigment optical density (MPOD) measurement by heterochromatic flicker photometry has earned a Category III CPT Code from the American Medical Association. While this code does not receive paid reimbursement, Category III CPT Codes are used for da
- Sue Anschutz-Rodgers Eye Center: A Highly Visible Legacy of Longstanding Philanthropic Partnershiphttps://modernod.com/news/sue-anschutz-rodgers-eye-center-a-highly-visible-legacy-of-longstanding-philanthropic-partnership/2480040/The University of Colorado Anschutz Medical Campus and UCHealth announced the naming of the UCHealth Eye Center program for philanthropist Sue Anschutz-Rodgers, who has made leadership gifts to accelerate innovative r
- EyeSouth Partners Develops of Physician Advisory Boardhttps://modernod.com/news/eyesouth-partners-develops-of-physician-advisory-board/2480041/As part of its continuing focus on the highest quality patient outcomes, EyeSouth Partners, a network of integrated eye care practices located throughout the Southeast, announced the formation of its physician advisory board. Its responsibilities will include overseeing clinical policies and proc
- Elsalys Biotech: New Studies Confirm Anti-CD160 Potential in Ophthalmologyhttps://modernod.com/news/elsalys-biotech-new-studies-confirm-anti-cd160-potential-in-ophthalmology/2480045/Elsalys Biotech, announced the publication of two studies validating the potential of its first-in-class anti-CD160 antibodies for the treatment of neovascular diseases of the eye. The first study reveals that in patients, CD160 endothelial expression in ret
- Prevent Blindness to Hold “Eyes on Capitol Hill” Advocacy Eventhttps://modernod.com/news/prevent-blindness-to-hold-thirteenth-annual-eyes-on-capitol-hill-advocacy-event/2480051/Prevent Blindness will be holding its 13th annual “Eyes on Capitol Hill” advocacy day on July 17, 2018, in Washington DC. Prevent Blindness and its affiliates will bring together citizens from across the country to meet with Congress and their staff to speak on vision issues and to request suppor
- Ocugen Initiates Phase 3 Clinical Trial of OCU300 for the Treatment of Ocular Graft Versus Host Diseasehttps://modernod.com/news/ocugen-initiates-phase-3-clinical-trial-of-ocu300-for-the-treatment-of-ocular-graft-versus-host-disease/2480053/Ocugen announced that it has initiated the first of two pivotal, phase 3 clinical trials of OCU300 for the treatment of ocular discomfort and ocular redness in patients with ocular graft versus host disease (oGVHD) following recent acceptance of Ocugen’s investigational new drug (IND) appli
- Lin BioScience Receives EMA Orphan Drug Status for LBS-008 for the Treatment of Stargardt Diseasehttps://modernod.com/news/lin-bioscience-receives-ema-orphan-drug-status-for-lbs-008-for-the-treatment-of-stargardt-disease/2480056/Lin BioScience announced that the European Medicines Agency has granted orphan drug designation to LBS-008, a first-in-class oral therapy for the treatment of Stargardt Disease. Stargardt Disease is currently an untreatable inherited condition that causes permanent vision loss in children
- Former P&G And Cincinnati Children’s Executive Katherine Overbey Joins OneSight As President And Executive Directorhttps://modernod.com/news/former-pg-and-cincinnati-childrens-executive-katherine-overbey-joins-onesight-as-president-and-executive-director/2480057/Global vision care nonprofit OneSight announced that Katherine “K-T” Overbey will be joining the organization as President and Executive Director. Ms. Overbey brings a distinct blend of blue-chip corporate and nonprofit experience in both developed and emerging markets, as well as a s
- Novaliq’s NovaTears Treatment for Evaporative Dry Eye Disease is Now Available across Australia and New Zealandhttps://modernod.com/news/novaliqs-novatears-treatment-for-evaporative-dry-eye-disease-is-now-available-across-australia-and-new-zealand/2480059/Novaliq announced that NovaTears, a novel topical treatment of dry eye disease and meibomian gland dysfunction (MGD), is now also available in Australia. Just 8 months after launching in New Zealand, AFT Pharmaceuticals Ltd (AFT) has achieved registration of NovaTears in Australia. AFT, a
- Oyster Point Pharma Gets Green Light From FDA to Proceed With Clinical Development of Dry Eye Treatmenthttps://modernod.com/news/oyster-point-pharma-gets-green-light-from-fda-to-proceed-with-clinical-development-of-dry-eye-treatment/2480060/Oyster Point Pharma announced that the FDA has cleared the company’s investigational new drug (IND) application to proceed with clinical development of OC-01, an investigational compound intended to stimulate natural tear film production in people with dry eye disease that is administered with a